Figure 5.
Challenge with recombinant vaccinia virus. Protection against challenge with HIV gp160-expressing vaccinia virus (vPE16) was examined 15 weeks after the immunization. Three days after challenge, vaccinia virus titers were examined in mouse ovaries using a plaque assay (left panel) or β-galactosidase assay (right panel)